Cwm LLC Boosts Stock Position in Novartis AG $NVS

Cwm LLC increased its holdings in Novartis AG (NYSE:NVS) by 8.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 89,476 shares of the company’s stock after purchasing an additional 6,817 shares during the period. Cwm LLC’s holdings in Novartis were worth $11,474,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. GFG Capital LLC purchased a new position in shares of Novartis in the 2nd quarter worth $26,000. WPG Advisers LLC bought a new position in shares of Novartis in the 1st quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new position in shares of Novartis in the 2nd quarter valued at about $30,000. Barrett & Company Inc. purchased a new position in Novartis in the second quarter worth about $31,000. Finally, MCF Advisors LLC increased its stake in Novartis by 66.0% during the second quarter. MCF Advisors LLC now owns 264 shares of the company’s stock worth $32,000 after acquiring an additional 105 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Performance

NVS stock opened at $139.05 on Monday. Novartis AG has a twelve month low of $96.91 and a twelve month high of $140.18. The firm has a market cap of $293.74 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 1.97 and a beta of 0.52. The business’s fifty day simple moving average is $130.58 and its two-hundred day simple moving average is $125.56. The company has a quick ratio of 0.68, a current ratio of 0.88 and a debt-to-equity ratio of 0.50.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). The company had revenue of $14.36 billion for the quarter, compared to analysts’ expectations of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.06 earnings per share. Analysts predict that Novartis AG will post 8.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NVS. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research note on Monday, December 22nd. JPMorgan Chase & Co. upgraded Novartis from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Cfra set a $126.00 price objective on shares of Novartis and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Bank of America raised shares of Novartis from a “neutral” rating to a “buy” rating in a research note on Tuesday, November 25th. Finally, HSBC reaffirmed a “reduce” rating and set a $112.00 price target on shares of Novartis in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $119.75.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.